Skip to main content
ONO PHARMACEUTICAL CO., LTD. logo

ONO PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 4528 ISIN · JP3197600004 LEI · 529900G26L4NG4GFJZ86 T Manufacturing
Open in API
Filings indexed 65 across all filing types
Latest filing 2024-06-21 Annual Report
Country JP Japan
Listing T 4528

About ONO PHARMACEUTICAL CO., LTD.

https://www.ono-pharma.com/en

Ono Pharmaceutical Co., Ltd. is a research and development-oriented pharmaceutical company dedicated to discovering and developing innovative medicines. With a history spanning over 300 years since its founding in 1717, the company focuses on addressing unmet medical needs for patients worldwide. Its primary research and development areas are oncology, immunology, and neurology. Ono Pharmaceutical is committed to creating unique, first-in-class drugs and is particularly recognized for its pioneering work in the field of immuno-oncology. The company's portfolio consists of prescription pharmaceuticals aimed at treating a range of diseases and conditions.

Recent filings

Filing Released Lang Actions
有価証券報告書－第76期(2023/04/01－2024/03/31)
Annual Report Classification · 100% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of a 10-K annual report. It contains the header information for the fiscal year ending March 31, 2024, for Ono Pharmaceutical Co., Ltd., and is filed with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It is a comprehensive annual financial disclosure document. FY 2024
2024-06-21 Japanese
臨時報告書
Share Issue/Capital Change Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report) and is submitted to the Kanto Local Finance Bureau Director ("関東財務局長"). The content details the resolution by the Board of Directors on June 20, 2024, regarding the disposal of common shares to directors and executive officers under existing stock compensation plans (System I and System II). This structure, involving the issuance of shares as compensation subject to transfer restrictions, is characteristic of filings related to capital changes, executive compensation, or specific corporate actions requiring immediate disclosure under Japanese financial regulations (specifically referencing Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act). Since the core subject is the issuance/disposal of shares to management as part of a compensation scheme, it strongly aligns with 'Share Issue/Capital Change' (SHA) or potentially 'Remuneration Information' (DEF 14A). However, the filing explicitly concerns the *disposal* (issuance) of new shares to executives as compensation, which is a direct capital structure event. Given the options, 'SHA' (Share Issue/Capital Change) is the most appropriate fit for a filing detailing the mechanics and recipients of a new share issuance, even if the underlying purpose is remuneration. It is not a standard 10-K, ER, or IR. It is a specific regulatory filing about capital movement, making SHA the best fit over the general RNS or the compensation-specific DEF 14A, as the mechanics of the share disposal are central.
2024-06-20 Japanese
臨時報告書
M&A Activity Classification · 100% confidence The document is titled with Japanese regulatory headers, specifically mentioning "【提出書類】 臨時報告書" (Filing Document: Extraordinary Report) and filed with the "関東財務局長" (Kanto Local Finance Bureau Director) on May 13, 2024. The content details the acquisition of a US company (Deciphera Pharmaceuticals, Inc.) for cash, outlining the rationale, target company financials, and the transaction price. In the Japanese regulatory context, an Extraordinary Report (臨時報告書) is typically filed under Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act (金融商品取引法) for significant events like M&A. This structure strongly aligns with a major corporate action disclosure. Among the provided codes, 'TAR' (M&A Activity) is the most specific fit for a document detailing a takeover/acquisition. Although it is technically an 'Extraordinary Report' (which might sometimes map to RNS), the subject matter is explicitly M&A, making TAR the superior classification over the general 'RNS' or 'LTR'. The document is comprehensive, not just an announcement of a report, so RPA/RNS is less appropriate than TAR.
2024-05-13 Japanese
四半期報告書－第76期第3四半期(2023/10/01－2023/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan, covering the third quarter of the 76th fiscal year (October 1, 2023, to December 31, 2023). It contains detailed financial statements, management analysis (MDA), and business updates, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-02-06 Japanese
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification by the CEO of Ono Pharmaceutical Co., Ltd., confirming the accuracy of the contents of the third-quarter report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type. Q3 76
2024-02-06 Japanese
臨時報告書
Board/Management Information Classification · 100% confidence The document is titled '臨時報告書' (Extraordinary Report) and is submitted to the Kanto Local Finance Bureau ('関東財務局長'). The submission date is January 12, 2024. Section 1 explicitly states the reason for filing: '当社は、2024年１月11日開催の取締役会において、代表取締役の異動について決議いたしましたので、金融商品取引法第24条の５第４項及び企業内容等の開示に関する内閣府令第19条第２項第９号の規定に基づき、本臨時報告書を提出するものであります。' (The Company resolved on the change of Representative Director at the Board of Directors meeting held on January 11, 2024, and is submitting this Extraordinary Report based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and Article 19, Paragraph 2, Item 9 of the Cabinet Office Ordinance on Disclosure of Corporate Information, etc.). This content directly relates to changes in senior management/board members. The closest matching category is 'Board/Management Information' (MANG). Although it is filed as an 'Extraordinary Report' (which might suggest RNS), the specific content is about management changes, making MANG the most precise classification.
2024-01-12 Japanese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.